Apyx Medical CorporationAPYXNASDAQ
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank74
5Y CAGR-10.2%
Year-over-Year Change
Year-over-year net income growth rate
5Y CAGR
-10.2%/yr
Long-term compound
Percentile
P74
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 34.53% |
| Q3 2025 | 47.49% |
| Q2 2025 | 8.96% |
| Q1 2025 | 10.33% |
| Q4 2024 | 1.59% |
| Q3 2024 | 28.26% |
| Q2 2024 | 13.46% |
| Q1 2024 | 21.14% |
| Q4 2023 | -107.54% |
| Q3 2023 | -365.69% |
| Q2 2023 | 71.46% |
| Q1 2023 | 42.42% |
| Q4 2022 | -4.94% |
| Q3 2022 | -6.23% |
| Q2 2022 | 8.73% |
| Q1 2022 | -196.80% |
| Q4 2021 | 52.56% |
| Q3 2021 | -4.35% |
| Q2 2021 | 17.45% |
| Q1 2021 | -220.96% |
| Q4 2020 | 59.04% |
| Q3 2020 | 20.51% |
| Q2 2020 | -140.39% |
| Q1 2020 | 66.40% |
| Q4 2019 | -34.68% |
| Q3 2019 | 0.62% |
| Q2 2019 | 7.33% |
| Q1 2019 | -18.27% |
| Q4 2018 | -105.72% |
| Q3 2018 | 25531.62% |
| Q2 2018 | 70.91% |
| Q1 2018 | -13.47% |
| Q4 2017 | 33.82% |
| Q3 2017 | 4.82% |
| Q2 2017 | 22.37% |
| Q1 2017 | -222.18% |
| Q4 2016 | 45.75% |
| Q3 2016 | -85.74% |
| Q2 2016 | 73.30% |
| Q1 2016 | -37.87% |